Company news

Genetic Signatures Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Half Yearly Report and Accounts

February 25, 2025

$5m R&D Tax Incentive Received

November 21, 2024

2024 AGM Chairman's Address and CEO Presentation

November 19, 2024

Appendix 4E and Annual Report

August 30, 2024

Despatch Of Retail Entitlement Offer Booklet

June 12, 2024

Completion of Institutional Entitlement Offer and Placement

June 5, 2024

FDA Clearance and Capital Raising Presentation

June 4, 2024

Genetic Signatures Announces $30 Million Capital Raising

June 3, 2024

Genetic Signatures Appoints Allison Rossiter As CEO

June 3, 2024

FDA Clearance For Gastrointestinal Parasite Detection Kit

June 3, 2024

Trading Halt

May 31, 2024

Decision to Cease Development of US Respiratory Product

May 26, 2024

Leadership Transition at Genetic Signatures

April 29, 2024

TGA authorises supply of updated Respiratory Detection Kit

April 21, 2024

1H 24 Market Update

February 21, 2024

Genetic Signatures Rights Issue Offer Booklet

January 1, 2024

Genetic Signatures Successfully Completes Placement

December 28, 2023

Genetic Signatures Announces $15.9m Capital Raising

December 20, 2023

Capital Raising Presentation

December 20, 2023

$6.9m R&D tax incentive received

December 18, 2023

2023 AGM Chairman's Address and CEO Presentation

November 28, 2023

Quarterly update and Appendix 4C

October 29, 2023

510(k) Filing in Preparation for US Commercial Launch

September 3, 2023

FDA 510(k) for Gastrointestinal Parasite Kit Submitted

September 3, 2023

Influenza B Detection Expected to Impact on Quarter Sales

August 24, 2023

Response to ASX Query

October 3, 2022

3base Kit for Antimicrobial Resistance Shows High Detection

September 28, 2022

Full Year Statutory Accounts

August 31, 2022

Clinical trial recruitment completed for US enteric kit

July 26, 2022

Public Health Wales Awards Enteric Testing Contract to GSS

March 29, 2022

S&P DJI Announces March 2022 Quarterly Rebalance

March 4, 2022

3base SARS-CoV-2 kit registered by TGA for saliva samples

January 9, 2022

Investor update

December 21, 2021

CE-IVD received for STI test

January 27, 2021

Supply agreement with major US customer

December 23, 2020

First quarter sales update

October 1, 2020

Preliminary Final Report

August 27, 2020

Quarterly report and Appendix 4C

July 27, 2020

S&P DJI Announces June 2020 Quarterly Rebalance

June 11, 2020

Appendix 4C & quarterly update

April 29, 2020

TGA registration of SARS-CoV-2 detection kit

April 14, 2020

CE-IVD received for COVID-19 test

April 1, 2020

First shipments and regulatory submissions for COVID-19 test

March 30, 2020

Pause in Trading

March 26, 2020

Appendix 4C & quarterly report

October 27, 2019

Investor presentation - capital raise

October 27, 2019

Genetic Signatures completes $35m placement

October 27, 2019

Appendix 4E & Full Year Statutory Accounts

August 27, 2019

Appendix 4C and quarterly update

July 24, 2019

TGA registration for Respiratory Pathogen Detection Kit

May 27, 2019

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 47 decks. Every deck is listed under its year.